-
Cryofocus Biotechnology Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D
•
Cryofocus Biotechnology Co., Ltd (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the First Affiliated Hospital of Guangzhou Medical University have entered into a collaborative agreement to contribute to the Guangzhou Lab’s project establishment and management. Guangzhou Lab is a cutting-edge research institution dedicated to the prevention and control…
-
Cryofocus Biotechnology Partners with Boston Scientific for Respiratory Products Distribution in China
•
Cryofocus Biotechnology Co., Ltd (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced a strategic distribution agreement with the Shanghai subsidiary of US medical device giant Boston Scientific Corporation (NYSE: BSX). As per the terms of the agreement, Cryofocus is set to become the exclusive marketing partner and sales…
-
Cryofocus Biotechnology Secures NMPA Approval for Cryotherapy Equipmen
•
Shanghai-based Cryofocus Biotechnology Co., Ltd. (HKG: 6922) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its cryotherapy equipment, which supports its innovative frozen adhesion treatment system. The cryotherapy equipment comprises a main unit, a foot switch, and an exhaust pipe, and is…
-
Cryofocus Biotechnology Receives NMPA Approval for Complete Cardiac Cryoablation System
•
Cryofocus Biotechnology Co., Ltd (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced that it has received marketing approvals from China’s National Medical Products Administration (NMPA) for all components of its cardiac cryoablation system. The approvals include the cryoablation equipment, balloon type cryoablation catheter (previously known as the atrial…
